

Remarks

Pursuant to the Restriction Requirement, applicants elect Group I (claims 1, 2, 11 and 12, in part).

Applicants have amended claims 4 and 7 to provide that the compound is a homer expression modifying compound as is required by the claims of Group I and request modification of the Restriction Requirement to include claims 4-7 in Group I since all these claims relate to the treatment of neuropletic diseases or disorders by the administration of a homer expression modifying compound.

Favorable consideration of claims 1, 2, 4-7, 11 and 12 is respectfully requested.

Applicants reserve the right to file divisional applications to the non-elected subject matter.

If any fees are incurred as a result of the filing of this paper, authorization is given to charge Deposit Account No. 23-0785.

Respectfully submitted, .

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER



Martin L. Katz, Reg. No. 25,011

Date: October 25, 2004

Citicorp Center, Suite 3800
500 W. Madison Street
Chicago, IL 60661-2511
(312) 876-1800